IMV's Lead Immunotherapy to be Investigated in Breast Cancer
Press release content from Business Wire. The AP news staff was not involved in its creation. IMV’s Lead Immunotherapy to be Investigated in Breast Cancer May 10, 2021 GMT DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--May 10, 2021-- IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that its lead compound, maveropepimut-S (DPX-Survivac) will be investigated in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. HR+/HER2- tumors represent an u...
Source: apnews.com